Item 8.01. Other Events.
On January 4, 2021, Zosano Pharma Corporation issued a press release announcing
that it has submitted a Type A meeting request to the U.S. Food and Drug
Administration ("FDA") to discuss the complete response letter received from the
FDA in connection with the Qtrypta™ (zolmitriptan transdermal microneedle
system) 505(b)(2) New Drug Application. A copy of the press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by
reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Description
99.1 Press Release dated January 4, 2021 titled "Zosano Pharma Requests Type
A Meeting with the FDA to Review Resubmission Plans for Qtrypta™ New Drug
Application"
104.1 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses